GlassScriptPhysician profile
Kevin Patrick Gibbs
NPI 1316209513
$6,774.04
in general payments reported to CMS, 2019-2025
64 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 91% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $227 · 2022: $561 · 2023: $766 · 2024: $2,284 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,413.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.24 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $423.49 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $422.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $388.14 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Janssen Biotech, INC. | $311.78 | 2022-2025 | Erleada, Rybrevant, Balversa |
| Genentech USA, INC. | $295.57 | 2022-2025 | Polivy, Tecentriq, Itovebi |
| Lilly USA, LLC | $246.97 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $185.93 | 2019-2025 | Injectafer, Enhertu |
| Eagle Pharmaceuticals, INC. | $174.15 | 2024 | |
| Aveo Pharmaceuticals, INC. | $166.31 | 2023-2025 | Fotivda |
| Incyte Corporation | $156.76 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Sirtex Medical INC | $148.78 | 2019 | |
| Puma Biotechnology, INC. | $148.04 | 2019-2025 | |
| Genmab U.S., INC. | $138.98 | 2023-2025 | Tivdak, Epkinly |
| Abbvie INC. | $137.31 | 2019-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $125.37 | 2019-2025 | Onivyde, Somatuline Depot |
| Eisai INC. | $120.17 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $117.95 | 2022-2025 | |
| Foundation Medicine, INC. | $114.67 | 2020 | |
| Jazz Pharmaceuticals INC. | $109.47 | 2023-2025 | |
| Emd Serono, INC. | $108.35 | 2023-2025 | Tepmetko |
| Taiho Oncology, INC. | $104.06 | 2020-2025 | Inqovi, Lonsurf |
| Adc Therapeutics America, INC. | $102.67 | 2022-2025 | |
| Glaxosmithkline, LLC. | $98.67 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $97.10 | 2024-2025 | |
| Immunocore Limited | $94.58 | 2024-2025 | Kimmtrak |
| Rigel Pharmaceuticals, INC. | $90.82 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $86.89 | 2023-2025 | Libtayo |
| Amgen INC. | $86.52 | 2019 | |
| Sobi, INC | $86.22 | 2023-2025 | |
| Spectrum Pharmaceuticals INC. | $77.56 | 2024-2025 | Rolvedon |
| Exelixis INC. | $75.58 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $70.15 | 2020-2024 | |
| Mirati Therapeutics, INC. | $69.89 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $66.64 | 2025 | Orserdu |
| G1 Therapeutics, INC. | $62.99 | 2022 | |
| Seagen INC. | $59.73 | 2019-2023 | Adcetris, Tukysa |
| Sumitomo Pharma America, INC. | $58.12 | 2024-2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $54.38 | 2024-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.02 | 2025 | |
| Beigene USA, INC. | $49.58 | 2024 | Brukinsa |
| Genzyme Corporation | $47.15 | 2025 | |
| Morphosys, US INC. | $45.90 | 2022-2023 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $44.96 | 2024 | Ultomiris |
| Astellas Pharma US INC | $43.85 | 2019-2024 | Padcev |
| Beone Medicines USA, INC. | $38.26 | 2025 | Brukinsa, Tevimbra |
| Springworks Therapeutics, INC. | $29.82 | 2024 | Ogsiveo |
| Gilead Sciences, INC. | $28.89 | 2025 | Trodelvy |
| Secura Bio, INC. | $27.30 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $26.28 | 2019-2022 | |
| Genentech, INC. | $25.79 | 2024 | Lunsumio, Columvi |
| Blueprint Medicines Corporation | $25.59 | 2022-2023 | Ayvakit |
| Exact Sciences Corporation | $25.33 | 2025 | Cologuard Collection Kit |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $23.45 | 2024 | Besremi |
| Novocure INC. | $22.74 | 2025 | Optune Lua (Novottf-200t) |
| Verastem, INC. | $19.77 | 2025 | Avmapki Fakzynja Co-Pack |
| Kyowa Kirin, INC. | $18.03 | 2024 | Poteligeo |
| Myovant Sciences INC. | $17.19 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.79 | 2023 | Monoferric |
| Coherus Oncology, INC. | $14.32 | 2025 | Loqtorzi |
| Dova Pharmaceuticals | $12.81 | 2020 | |
| Agios Pharmaceuticals, INC. | $11.53 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.